Investment Thesis
Quoin Pharmaceuticals is a pre-revenue biotech company with acute financial distress, burning $4.9M in operating cash annually against only $3.1M in cash reserves, resulting in approximately 6-7 months of runway. The company exhibits severe fundamental weakness with negative operating income of -$15.8M, negative ROE of -57% and ROA of -31.8%, with no visible revenue generation or path to near-term profitability, creating existential solvency risk.
Strengths
- Strong liquidity position with current ratio of 2.87x and quick ratio of 2.87x provides near-term operational flexibility
- Zero debt burden (Debt/Equity ratio of 0.00x) minimizes financial leverage risk and avoids debt servicing pressure
- Positive stockholders equity of $8.8M maintains solvency status despite operational losses
Risks
- Pre-revenue status with no sales generation creates dependency on capital infusions for survival
- Critical cash runway of approximately 6-7 months at current burn rate threatens continued operations without financing
- Persistent operating losses of -$15.8M with negative returns on equity (-57%) and assets (-31.8%) indicate rapid shareholder value destruction
- Operating cash flow of -$4.9M demonstrates cash burn exceeds revenue generation by significant margin
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway until insolvency
- Pipeline milestone achievements and clinical trial progress toward revenue generation
- Management's capital raising activities and dilution impact on equity holders
Financial Metrics
Revenue
N/A
Net Income
-5.0M
EPS (Diluted)
$0.00
Free Cash Flow
-4.9M
Total Assets
15.7M
Cash
3.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-57.0%
ROA
-31.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.87x
Quick Ratio
2.87x
Debt/Equity
0.00x
Debt/Assets
44.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T12:44:55.141808 |
Data as of: 2026-03-31 |
Powered by Claude AI